Global Pharmaceutical Contract Manufacturing Industry
NEW YORK, July 26, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Pharmaceutical Contract Manufacturing Industryhttp://www.reportlinker.com/p098296/Global-Pharmaceutical-Contract-Manufacturing-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceu
This report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in US$ Million by the following Dosage Forms: Injectables (Injections, Vials, and IV solutions), Solid Dosage Forms (Tablets and Capsules), and Liquid Dosage Forms (Syrups and Suspensions). The report provides separate comprehensive analytics for the USA, Canada, Japan, Europe, Asia-Pacific and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 82 companies including many key and niche players such as Althea Technologies, Catalent Pharma Solutions, Dishman Pharmaceuticals and Chemicals Ltd, HAUPT Pharma AG, Jubilant Life Sciences Limited, Kemwell Pvt. Ltd, NextPharma, Nipro Corp., Patheon, Inc., Penn Pharmaceutical Services Ltd. and Royal DSM N.V. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations I-1Disclaimers I-2Data Interpretation & Reporting Level I-2Quantitative Techniques & Analytics I-3Product Definitions and Scope of Study I-3II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW II-1
Recession Lashes Global Pharmaceutical Contract Manufacturing
Industry II-1
Recession Bodes Better Long Term Prospects II-1
Major Changes Imperative to Capitalize on Brighter Future
Prospects II-2
Asia Dominates Regional Growth, North America Retains Position
as Largest Market II-2
Solid Dosage Form Continues to Remain Popular Among Pharma
Contract Manufacturers II-3
Generic Drugs: A Business Case for PCM's of Solid Drugs II-3
Biopharmaceutical Contract Manufacturing Market to Surge II-4
PCM - A Highly Fragmented Industry II-4
Table 1: Leading Players in the Global Pharmaceutical
Contract Manufacturing Market (2009): Percentage Breakdown of
Revenues for Catalent, Patheon, Vetter, Baxter, Famar and
Others (includes corresponding Graph/Chart) II-4
Key Drivers of the Market II-5
2. SERVICE OVERVIEW II-6Introduction II-6Injectables (injections, vials, and IV solutions) II-6Solid Dosage Forms (SDFs) (Tablets and Capsules) II-6Liquid Dosage Forms (LDFs) (Syrups and Suspensions) II-7An Insight into the Rise of Pharmaceutical Contract Manufacturing II-7A Focus on Bio-Manufacturing II-8
3. MARKET DYNAMICS II-9
Outsourcing Emerges as a Strategic Priority for Pharmaceutical
Companies II-9
APIs Account for a Larger Share, While Finished Dosage Would
Drive Growth of PCM Market II-9
Is One Stop the Ideal Form of Contract Manufacturing? II-9
Virtual Pharma vs. Blockbuster Model II-10
Increased Scrutiny: A Case of Concern for the Industry II-10
Investment Risks in Pharmaceutical Contract II-10
Quality Assurance Risk II-10
Drug Development Risk II-11
Acquisition Risk II-11
Client Dependency Risk II-11
4. RECENT INDUSTRY ACTIVITY II-12Catalent Pharma Enters into a License Agreement with Pantec AG II-12Glatt Unveils New cGMP Capacity for Tablet and Capsule Production II-12MDS Divests MDS Pharma Services II-12Merck Closes Avecia Acquisition II-13Watson Acquires Eden Biopharm II-13Claris Life Sciences to Expand Drug Supply Services II-13Ranbaxy Inks Agreement to Take Over Assets of Biovel Lifesciences II-13Indoco to Enhance CRAMS Capabilities II-14AlphaRx Inks API Supply Agreement with Venturepharm II-15Alfresca Pharma to Enhance Contract Manufacturing Capabilities II-15Jubilant Realigns Newly Acquired Companies HollisterStier andDRAXIS II-15Bausch & Lomb Acquires Assets of Tubilux Pharma II-15Sigma Pharmaceuticals to Acquire Pharmaceutical Brands andManufacturing Facility of BMS II-16Walter Street Acquires AAIPharma's Pharmaceutical DevelopmentDivision II-16Lonza Plans Acquisition of Patheon for US$ 460 Million II-17Daiichi Sankyo and CMIC Ink Pact for Transferring Shizuoka Plant II-17Novasep Acquires Henogen II-18First Boston Pharma Buys NutraMax Products II-18Boehringer Ingelheim Renews Chemistry Services Agreement withDalton Pharma II-19Selexys Appoints Cytovance as a Contract Manufacturer forCrohn's Disease Drug II-19
5. STRATEGIC CORPORATE DEVELOPMENTS - A HISTORICPERSPECTIVE BUILDER II-20
Fresenius Kabi Pharmaceuticals Acquires APP Pharmaceuticals II-20
Recordati Enters into an Agreement to Acquire Yeni Ilac II-20
Laureate Pharma Inks a Contract Manufacturing Pact with Tolera
Therapeutics II-20
Akorn Signs Exclusive Contract Manufacturing Agreement II-20
Haupt Pharma Merges with Wülfing Pharma and AMAREG II-21
United Drug Announces Acquisition of Sharp Corporation II-21
Oso Biopharmaceuticals to Acquire Albuquerque Injectables
Business II-21
Dr. Reddy's Laboratories Acquires PCM Business of BASF II-21
Medikalla and Probio to Form a New Joint Venture Finbio II-22
Dragenopharm Merge With Swiss Caps and Form AENOVA II-22
Akorn Signs Contract Manufacturing Pact with a Leading US
Pharmaceutical Firm II-23
Jubilant Acquires Draxis for US$ 253 Million II-23
JHP Acquires Assets of King Pharmaceuticals II-23
NextPharma Acquires Bioserv Corporation II-23
PharmAthene to Acquire Avecia's Biodefense Vaccine Operations II-24
Bioserv Enters into an Outsourcing Agreement with BioLife
Solutions II-24
Eden Biodesign and Stealthyx Therapeutics Ink an Agreement II-25
NPIL Pharma to Expand HPS Sites in Scotland II-25
Dishman Pharma Installs New API Facilities II-25
Patheon Divests Niagara-Burlington Manufacturing Business to
Pharmetics II-26
Jubilant Organosys Acquires Hollister-Stier Laboratories II-26
Hikma Pharmaceuticals Acquires Thymoorgan GmbH Pharmazie II-26
Meda Acquires Recip II-27
Keata Pharma Acquires Pfizer's Production Facility in Canada II-27
STADA Acquires MAKIZ II-28
Nextpharma to Expand its Cytostatics Production Facility II-28
Haupt Pharma Establishes Production Facility in Malta II-29
Kemwell Pockets Pfizer's Uppsala Sweden Based Manufacturing Plant II-29
Crucell and DSM Biologics Enter into a Licensing Agreement
with UMN Pharma II-29
Lannett Inks a Multi-Product Contract Manufacturing Agreement
with Wintac II-30
ATOZ Establishes Soft Gelatin Manufacturing Facility in
Himachal Pradesh, India II-30
BASF Buys Orgamol SA II-30
Federa Completes Construction of Prefilled Syringes Facility II-30
BioProgress PLC Signs an Agreement with Custom Pharmaceuticals II-31
Safeguard Scientifics Acquires Laureate II-31
6. FOCUS ON SELECT GLOBAL PLAYERS II-32Althea Technologies (USA) II-32Catalent Pharma Solutions (USA) II-32Dishman Pharmaceuticals and Chemicals Ltd (India) II-32HAUPT Pharma AG (Germany) II-32Jubilant Life Sciences Limited (India) II-32Kemwell Pvt. Ltd (India) II-33NextPharma (UK) II-33Nipro Corp. (Japan) II-33Patheon, Inc. (Canada) II-33Penn Pharmaceutical Services Ltd. (UK) II-34Royal DSM N.V. (The Netherlands) II-34
7. GLOBAL MARKET PERSPECTIVE II-35
Table 2: World Recent Past, Current and Future Analysis for
Pharmaceutical Contract Manufacturing by Geographic Region -
US, Canada, Japan, Europe, Asia-Pacific and Rest of World
Markets Independently Analyzed with Annual Revenue in US$
Million for the Years 2009 through 2017 (includes
corresponding Graph/Chart) II-35
Table 3: World Historic Review for Pharmaceutical ContractManufacturing by Geographic Region - US, Canada, Japan,Europe, Asia-Pacific and Rest of World Markets IndependentlyAnalyzed with Annual Revenue Figures in US$ Million for theYears 2003 through 2008 (includes corresponding Graph/Chart) II-36
Table 4: World 15-Year Perspective for Pharmaceutical Contract
Manufacturing by Geographic Region - Percentage Breakdown of
Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific
and Rest of World Markets for the Years 2003, 2011 and 2017
(includes corresponding Graph/Chart) II-37
Table 5: World Recent Past, Current and Future Analysis forPharmaceutical Contract Manufacturing of Injectables(Injections, Vials & Intravenous Solutions) by GeographicRegion - US, Canada, Japan, Europe, Asia-Pacific and Rest ofWorld Markets Independently Analyzed with Annual RevenueFigures in US$ Million for the Years 2009 through 2017(includes corresponding Graph/Chart) II-38
Table 6: World Historic Review for Pharmaceutical Contract
Manufacturing of Injectables (Injections, Vials & Intravenous
Solutions) by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific and Rest of World Markets Independently Analyzed
with Annual Revenue Figures in US$ Million for the Years 2003
through 2008 (includes corresponding Graph/Chart) II-39
Table 7: World 15-Year Perspective for Pharmaceutical ContractManufacturing of Injectables (Injections, Vials & IntravenousSolutions) by Geographic Region - Percentage Breakdown ofAnnual Revenues for US, Canada, Japan, Europe, Asia-Pacificand Rest of World Markets for the Years 2003, 2011 and 2017(includes corresponding Graph/Chart) II-40
Table 8: World Recent Past, Current and Future Analysis for
Pharmaceutical Contract Manufacturing of Solid Dosage Forms
(Tablets & Capsules) by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific and Rest of World Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for the
Years 2009 through 2017 (includes corresponding Graph/Chart) II-41
Table 9: World Historic Review for Pharmaceutical ContractManufacturing of Solid Dosage Forms (Tablets & Capsules) byGeographic Region - US, Canada, Japan, Europe, Asia-Pacificand Rest of World Markets Independently Analyzed with AnnualRevenue Figures in US$ Million for the Years 2003 through 2008(includes corresponding Graph/Chart) II-42
Table 10: World 15-Year Perspective for Pharmaceutical
Contract Manufacturing of Solid Dosage Forms (Tablets &
Capsules) by Geographic Region - Percentage Breakdown of
Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific
and Rest of World Markets for the Years 2003, 2011 and 2017
(includes corresponding Graph/Chart) II-43
Table 11: World Recent Past, Current and Future Analysis forPharmaceutical Contract Manufacturing of Liquid Dosage Forms(Syrups & Suspensions) by Geographic Region - US, Canada,Japan, Europe, Asia-Pacific and Rest of World MarketsIndependently Analyzed with Annual Revenue Figures in US$Million for the Years 2009 through 2017 (includescorresponding Graph/Chart) II-44
Table 12: World Historic Review for Pharmaceutical Contract
Manufacturing of Liquid Dosage Forms (Syrups & Suspensions) by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
and Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for the Years 2003 through 2008
(includes corresponding Graph/Chart) II-45
Table 13: World 15-Year Perspective for PharmaceuticalContract Manufacturing of Liquid Dosage Forms (Syrups &Suspensions) by Geographic Region - Percentage Breakdown ofAnnual Revenues for US, Canada, Japan, Europe, Asia- Pacificand Rest of World Markets for the Years 2003, 2011 and 2017(includes corresponding Graph/Chart) II-46III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
Trends III-1
Pharma Companies Increasingly Outsource Manufacturing Activity III-1
Injectables Segment Witnesses Upward Growth Trend III-1
Competitive Landscape III-1
B.Market Analytics III-2
Table 14: US Recent Past, Current and Future Analysis for
Pharmaceutical Contract Manufacturing by Dosage Form -
Injectables (Injections, Vials & Intravenous Solutions),
Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage
Forms (Syrups & Suspensions) Independently Analyzed with
Annual Revenue Figures in US$ Million for the Years 2009
through 2017 (includes corresponding Graph/Chart) III-2
Table 15: US Historic Review for Pharmaceutical ContractManufacturing by Dosage Form - Injectables (Injections,Vials & Intravenous Solutions), Solid Dosage Forms (Tablets& Capsules) and Liquid Dosage Forms (Syrups & Suspensions)Independently Analyzed with Annual Revenue Figures in US$Million for the Years 2003 through 2008 (includescorresponding Graph/Chart) III-3
Table 16: US 15-Year Perspective for Pharmaceutical Contract
Manufacturing by Dosage Form - Percentage Breakdown of
Annual Revenues for Injectables (Injections, Vials &
Intravenous Solutions), Solid Dosage Forms (Tablets &
Capsules) and Liquid Dosage Forms (Syrups & Suspensions) for
the Years 2003, 2011 and 2017 (includes corresponding
Graph/Chart) III-4
2. CANADA III-5Market Analytics III-5Table 17: Canadian Recent Past, Current and Future Analysisfor Pharmaceutical Contract Manufacturing by Dosage Form -Injectables (Injections, Vials & Intravenous Solutions),Solid Dosage Forms (Tablets & Capsules) and Liquid DosageForms (Syrups & Suspensions) Independently Analyzed withAnnual Revenue Figures in US$ Million for the Years 2009through 2017 (includes corresponding Graph/Chart) III-5
Table 18: Canadian Historic Review for Pharmaceutical
Contract Manufacturing by Dosage Form - Injectables
(Injections, Vials & Intravenous Solutions), Solid Dosage
Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups &
Suspensions) Independently Analyzed with Annual Revenue
Figures in US$ Million for the Years 2003 through 2008
(includes corresponding Graph/Chart) III-6
Table 19: Canadian 15-Year Perspective for PharmaceuticalContract Manufacturing by Dosage Form - Percentage Breakdownof Annual Revenues for Injectables (Injections, Vials &Intravenous Solutions), Solid Dosage Forms (Tablets &Capsules) and Liquid Dosage Forms (Syrups & Suspensions) forthe Years 2003, 2011 and 2017 (includes correspondingGraph/Chart) III-7
3. JAPAN III-8
A.Market Analysis III-8
Impact of Contract Manufacturing on Japanese Pharmaceutical
Sector III-8
B.Market Analytics III-8
Table 20: Japanese Recent Past, Current and Future Analysis
for Pharmaceutical Contract Manufacturing by Dosage Form -
Injectables (Injections, Vials & Intravenous Solutions),
Solid Dosage Forms (Tablets & Capsules) and Liquid Dosage
Forms (Syrups & Suspensions) Independently Analyzed with
Annual Revenue Figures in US$ Million for the Years 2009
through 2017 (includes corresponding Graph/Chart) III-8
Table 21: Japanese Historic Review for PharmaceuticalContract Manufacturing by Dosage Form - Injectables(Injections, Vials & Intravenous Solutions), Solid DosageForms (Tablets & Capsules) and Liquid Dosage Forms (Syrups &Suspensions) Independently Analyzed with Annual RevenueFigures in US$ Million for the Years 2003 through 2008(includes corresponding Graph/Chart) III-9
Table 22: Japanese 15-Year Perspective for Pharmaceutical
Contract Manufacturing by Dosage Form - Percentage Breakdown
of Annual Revenues for Injectables (Injections, Vials &
Intravenous Solutions), Solid Dosage Forms (Tablets &
Capsules) and Liquid Dosage Forms (Syrups & Suspensions) for
the Years 2003, 2011 and 2017 (includes corresponding
Graph/Chart) III-10
4. EUROPE III-11A.Market Analysis III-11Injectables Segment Offers Promising Potential III-11Competitive Scenario III-11B.Market Analytics III-12Table 23: European Recent Past, Current and Future Analysisfor Pharmaceutical Contract Manufacturing by Dosage Form -Injectables (Injections, Vials & Intravenous Solutions),Solid Dosage Forms (Tablets & Capsules) and Liquid DosageForms (Syrups & Suspensions) Independently Analyzed withAnnual Revenue Figures in US$ Million for the Years 2009through 2017 (includes corresponding Graph/Chart) III-12
Table 24: European Historic Review for Pharmaceutical
Contract Manufacturing by Dosage Form - Injectables
(Injections, Vials & Intravenous Solutions), Solid Dosage
Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups &
Suspensions) Independently Analyzed with Annual Revenue
Figures in US$ Million for the Years 2003 through 2008
(includes corresponding Graph/Chart) III-13
Table 25: European 15-Year Perspective for PharmaceuticalContract Manufacturing by Dosage Form - Percentage Breakdownof Annual Revenues for Injectables (Injections, Vials &Intravenous Solutions), Solid Dosage Forms (Tablets &Capsules) and Liquid Dosage Forms (Syrups & Suspensions) forthe Years 2003, 2011 and 2017 (includes correspondingGraph/Chart) III-14
5. ASIA-PACIFIC III-15
A.Market Analysis III-15
Trends III-15
Asia - Emerging Hub for Contract Manufacturing III-15
Upbeat Market for Pharmaceutical Contract Manufacturing III-15
Competitive Scenario III-15
China III-15
China's Pharmaceutical Outsourcing Industry Outlives
Recessionary Effects III-15
India III-16
Pharmaceutical Outsourcing Market Puffs Up III-16
B.Market Analytics III-17
Table 26: Asia-Pacific Recent Past, Current and Future
Analysis for Pharmaceutical Contract Manufacturing by Dosage
Form - Injectables (Injections, Vials & Intravenous
Solutions), Solid Dosage Forms (Tablets & Capsules) and
Liquid Dosage Forms (Syrups & Suspensions) Independently
Analyzed with Annual Revenue Figures in US$ Million for the
Years 2009 through 2017 (includes corresponding Graph/Chart) III-17
Table 27: Asia-Pacific Historic Review for PharmaceuticalContract Manufacturing by Dosage Form - Injectables(Injections, Vials & Intravenous Solutions), Solid DosageForms (Tablets & Capsules) and Liquid Dosage Forms (Syrups &Suspensions) Independently Analyzed with Annual RevenueFigures in US$ Million for the Years 2003 through 2008(includes corresponding Graph/Chart) III-18
Table 28: Asia-Pacific 15-Year Perspective for
Pharmaceutical Contract Manufacturing by Dosage Form -
Percentage Breakdown of Annual Revenues for Injectables
(Injections, Vials & Intravenous Solutions), Solid Dosage
Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups &
Suspensions) for the Years 2003, 2011 and 2017 (includes
corresponding Graph/Chart) III-19
6. REST OF WORLD III-20Market Analytics III-20Table 29: Rest of World Recent Past, Current and FutureAnalysis for Pharmaceutical Contract Manufacturing by DosageForm - Injectables (Injections, Vials & IntravenousSolutions), Solid Dosage Forms (Tablets & Capsules) andLiquid Dosage Forms (Syrups & Suspensions) IndependentlyAnalyzed with Annual Revenue Figures in US$ Million for theYears 2009 through 2017 (includes corresponding Graph/Chart) III-20
Table 30: Rest of World Historic Review for Pharmaceutical
Contract Manufacturing by Dosage Form - Injectables
(Injections, Vials & Intravenous Solutions), Solid Dosage
Forms (Tablets & Capsules) and Liquid Dosage Forms (Syrups &
Suspensions) Independently Analyzed with Annual Revenue
Figures in US$ Million for the Years 2003 through 2008
(includes corresponding Graph/Chart) III-21
Table 31: Rest of World 15-Year Perspective forPharmaceutical Contract Manufacturing by Dosage Form -Percentage Breakdown of Annual Revenues for Injectables(Injections, Vials & Intravenous Solutions), Solid DosageForms (Tablets & Capsules) and Liquid Dosage Forms (Syrups &Suspensions) for the Years 2003, 2011 and 2017 (includescorresponding Graph/Chart) III-22IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 82 (including Divisions/Subsidiaries - 87)
------------------------------------------Region/Country Players------------------------------------------The United States 29Canada 6Japan 3Europe 33France 3Germany 8The United Kingdom 9Italy 4Rest of Europe 9Asia-Pacific (Excluding Japan) 16------------------------------------------
To order this report:Pharmaceutical Industry: Global Pharmaceutical Contract Manufacturing IndustryMore
Market Research ReportCheck our
Industry Analysis and InsightsContact
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article